GB1314051A - Polypeptides and their derivatives - Google Patents
Polypeptides and their derivativesInfo
- Publication number
- GB1314051A GB1314051A GB2477970A GB1314051DA GB1314051A GB 1314051 A GB1314051 A GB 1314051A GB 2477970 A GB2477970 A GB 2477970A GB 1314051D A GB1314051D A GB 1314051DA GB 1314051 A GB1314051 A GB 1314051A
- Authority
- GB
- United Kingdom
- Prior art keywords
- thr
- leu
- ser
- boc
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1314051 Polypeptides SANDOZ Ltd 22 May 1970 [3 June 1969 20 June 1969 (4) 23 June 1969 (3) 26 June 1969 30 June 1969 9 Sept 1969] 24779/70 Heading C2C Novel compounds I: S - CH 2 - CHX - CO - ser - asn - leu - ser - thr - cys - val - leu - gly - lys - leu - ser - gln - glu - leu - hislys - leu - gln - thr - tyr - pro - arg - thr - asnthr-gly-ser-gly-thr-Y wherein X is H, NH 2 , RCONH or R<SP>1</SP>OCONH; R is alkyl or optionally substituted aryl or aralkyl; R<SP>1</SP> is alkyl, alkenyl or optionally substituted aryl or aralkyl; and Y is -pro-NH 2 or -pro-val-NH 2 ; wherein the terminal peptide unit -S-CH 2 -CHX-CO- has the L-configuration where X is NH 2 , RCONH or R<SP>1</SP>OCONH; and wherein ser may be exchanged for thr or ala; asn for asp, gln or glu; thr for ser or ala; lys for lys(BOC), orn; asn or asp; glu for glu(OtBn), gln, asn or asp; leu for tyr; tyr for phe and arg for orn or lys, provided that when sequence is asin I, and Y is -pro-NH 2 , X is other than NH 2 , are prepared by normal methods of peptide synthesis. Intermediates isolated are Z- or H-thr-pro- NH 2 .HCl; Z-ser-gly-(OEt or NHNH 2 ); Z- or H - ser - gly - thr - pro - NH 2 ; Z - asn - thr - gly- OEt; Z - thr - asn - thr - gly - OEt; BOC- arg(NO 2 ) -thr - asn - thr - gly - (OEt or NHNH 2 ); (BOC or H) - arg - thr - asn - thr - gly - ser - glythr - pro - NH 2 ; (Z- or H-) thr - tyr - pro - (OH or OMe); Z-leu-gln-OMe; H-gln-OMe.HCl; Z- lys(BOC) - leu - gln - OMe: Z - his - lys(BOC)- leu - gln - (OMe or NHNH 2 ); Z - his - lys(BOC)- leu - gln - thr - tyr - pro - OH; Z - gln - thr - tyrpro - OH; Z - lys(BOC) - tyr(OMe); Z - hislys(BOC) - tyr - NHNH 2 ; Z - his - lys(BOC)- tyr - gln - thr - tyr - pro - OH; (Z or H) - hislys(BOC) - leu - gln - thr - tyr - pro - arg - thrasn - thr - gly - ser - gly - thr - pro - NH 2 ; H- his - lys(BOC) - tyr - gln - thr - tyr - pro - argthr - asn - thr - gly - ser - gly - thr - pro - NH 2 ; (H or Z) - glu(OtBn) - leu - OMe; (Z or H) - glnglu(OtBu) - leu - OMe; Z - lys(BOC) - leu - ser- OMe; trityl - gly - lys(BOC) - leu - ser - NHNH 2 ; trityl - gly - lys(BOC) - leu - ser - gln - glu(OtBn)- leu - (NHNH 2 or OMe); H - gly - lys(BOC) - leuser - gln - glu(OtBn) - leu - his - lys(BOC) - leugln - thr - tyr - pro - arg - thr - asn - thr - gly- ser - gly - thr - pro - NH 2 ; (H or Z) - gln - leu- OMe; (H or Z) - glu - gln - leu - OMe; tritylgly - lys(BOC) - leu - ser - gin - gln - leu- NHNH 2 ; H - gly - lys(BOC) - leu - ser - glngln - leu - his - lys(BOC) - leu - gln - thr - tyrpro - arg - thr - asn - thr - gly - ser - gly - thrpro - NH 2 ; H - gly - lys(BOC) - leu - ser - glnglu(OtBu) - leu - his - lys(BOC) - tyr - glu - thrtyr - pro - arg - thr - asn - thr - gly - ser - gly - thrpro - NH 2 ; H - gly - lys(BOC) - leu - ser - glngln - leu - his - lys(BOC) - tyr - gin - thr - tyrpro - arg - thr - asn - thr - gly - ser - gly - thrpro - NH 2 ; (H or Z) - cys(Bz) - val - leu - OMe; (H or Z) - thr - cys(Bz) - val - leu - OMe; H - thrcys(Bz) - val - leu - OH; (BOC or H) - asn - leuser - OMe; (BOC or H) - ser - asn - leu - ser- OMe; BOC - cys(Bz) - ser - asn - leu - ser- (NHNH 2 or OMe); BOC - cys - ser - asn - leuser - thr - cys - val - leu - OH; BOC - cys(Bz)- ser - asnleu - ser - thr - cys(Bz) - val - leu - OH; BOC - cys - ser - asn - leu-ser-thr-cys-val-leu- OH; pivaloyl - cys - ser - asn - leu - ser - thr - cysval-leu-OH; pivalic acid p-nitrophenyl ester; ethoxycarbonyl - cys - ser - arn - leu - ser - thr - cys - val-leu-OH; carbonic acid p-nitrophenyl ethyl ester; benzylmercaptopropionyl-ser-asn-leu-ser- # NHNH 2 ; and S-CH 2 CH 2 CO-ser - asn - leuser-thr-cys-val-leu-NHNH 2 . Pharmaceutical compositions comprise a compound I together with a suitable carrier and/or diluent and lower the calcium content in the blood.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH840569 | 1969-06-03 | ||
CH946169 | 1969-06-20 | ||
CH945369 | 1969-06-20 | ||
CH945169 | 1969-06-20 | ||
CH945269 | 1969-06-20 | ||
CH956069 | 1969-06-23 | ||
CH956169 | 1969-06-23 | ||
CH955969 | 1969-06-23 | ||
CH979269 | 1969-06-26 | ||
CH995769A CH515216A (en) | 1969-06-30 | 1969-06-30 | Synthetic polypeptides - salmon calcitonin derivs. with pharmacodynamic properties |
CH1361269 | 1969-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1314051A true GB1314051A (en) | 1973-04-18 |
Family
ID=27581430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB2477970A Expired GB1314051A (en) | 1969-06-03 | 1970-05-22 | Polypeptides and their derivatives |
Country Status (9)
Country | Link |
---|---|
JP (1) | JPS5429513B1 (en) |
CA (1) | CA967950A (en) |
DK (1) | DK144563C (en) |
FI (1) | FI54800C (en) |
GB (1) | GB1314051A (en) |
HK (1) | HK52476A (en) |
IE (1) | IE35077B1 (en) |
IL (1) | IL34630A (en) |
NO (1) | NO137087C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2130221A (en) * | 1982-11-18 | 1984-05-31 | Squibb & Sons Inc | Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides |
US4663309A (en) * | 1983-06-29 | 1987-05-05 | University Patents, Inc. | Novel peptide hormones with calcitonin-like activity |
-
1970
- 1970-05-22 GB GB2477970A patent/GB1314051A/en not_active Expired
- 1970-06-01 IL IL34630A patent/IL34630A/en unknown
- 1970-06-01 NO NO2120/70A patent/NO137087C/en unknown
- 1970-06-01 CA CA084,227A patent/CA967950A/en not_active Expired
- 1970-06-02 DK DK285470A patent/DK144563C/en not_active IP Right Cessation
- 1970-06-02 IE IE709/70A patent/IE35077B1/en unknown
- 1970-06-02 FI FI1558/70A patent/FI54800C/en active
- 1970-06-02 JP JP4711670A patent/JPS5429513B1/ja active Pending
-
1976
- 1976-08-19 HK HK524/76*UA patent/HK52476A/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2130221A (en) * | 1982-11-18 | 1984-05-31 | Squibb & Sons Inc | Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides |
US4663309A (en) * | 1983-06-29 | 1987-05-05 | University Patents, Inc. | Novel peptide hormones with calcitonin-like activity |
Also Published As
Publication number | Publication date |
---|---|
IL34630A (en) | 1973-10-25 |
DK144563C (en) | 1982-09-20 |
JPS5429513B1 (en) | 1979-09-25 |
CA967950A (en) | 1975-05-20 |
IE35077L (en) | 1970-12-03 |
NO137087B (en) | 1977-09-19 |
DK144563B (en) | 1982-03-29 |
FI54800B (en) | 1978-11-30 |
IE35077B1 (en) | 1975-11-12 |
FI54800C (en) | 1979-03-12 |
HK52476A (en) | 1976-08-27 |
IL34630A0 (en) | 1970-08-19 |
NO137087C (en) | 1977-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5132408A (en) | Fibroblast growth factor antagonists | |
IL92853A0 (en) | Human insulin analogues,their preparation and pharmaceutical compositions containing them | |
ES8203385A1 (en) | N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation. | |
GR3035067T3 (en) | Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins. | |
AU589674B2 (en) | GRF analogs | |
Manning et al. | Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism | |
HUP0003592A2 (en) | Lh-rh peptide analogues, their use and pharmaceutical compositions containing them | |
NL300013I2 (en) | New proteins with TNF inhibitory effect and their preparation. | |
GB1429700A (en) | Peptides having gastrin activity | |
DE3261304D1 (en) | Retro-inverso analogues of c-terminal penta and hexapeptides of substance p. | |
US5252718A (en) | Fibroblast growth factor antagonists | |
CA1187869A (en) | Deca- undeca- dodeca and tridecapeptides with thymic activity | |
GB1464774A (en) | 13-l-norleucine-14-desamido-motilin a method for preparing it and a therapeutic containing it | |
EP0037516A1 (en) | N-omega substituted derivatives of 1-Desamino-vasopressin analogs | |
GB1314051A (en) | Polypeptides and their derivatives | |
GB1526367A (en) | Polypeptide | |
GB1294771A (en) | Thyrocalcitonin derivative | |
EP0292257A3 (en) | Peptides having anf activity | |
US4597901A (en) | β-indolylalanyl or β-indolylglycinyl vasopressin antagonists | |
GB1316545A (en) | 1-alpha-aminoisobutyric acid-corticotropin peptides | |
GB1536878A (en) | Octapeptide | |
ES2001392A6 (en) | Polypeptides and preparation process thereof | |
ES8801315A1 (en) | Novel THF compositions. | |
US4122077A (en) | Somatostatin analogs | |
US4719199A (en) | Diuretic compositions and methods of producing diuresis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed [section 19, patents act 1949] | ||
PE20 | Patent expired after termination of 20 years |